eyeforpharma is now Reuters Events - LEARN MORE
Mary Assimakopoulos examines a common yet often unaddressed patient concern – the very human fear of needles!
While the pharmaceutical industry has found itself in a turbulent healthcare marketplace rife with changing regulations, new competitive challenges, and increasing pricing pressures, the end goal for manufacturers remains the same -- product reimbursement and optimal pricing.
Things are not what they used to be. In the good old days you could launch a drug and enjoy around seven years to reach peak sales. However, now the window is shorter and typically less than five years.
For the pharmaceutical rep, is the goal of patient retention in conflict with the more traditional goal of patient acquisition? Patient acquisition primarily demands a focus on the prescribing physician, whereas patient retention demands a focus on the patient. Is there even time for both?
by Ifti Ahmed
This month, Ifti Ahmed examines that age-old, often intimidating reality of any sales role - objections, and provides insights into how that 'no' could just be another opportunity for a 'yes'.
Dr Andree Bates explains while detailed analytics are imperative for sales and marketing.
What could motivate patients to show more concern for their pet’s health and medication adherence than their own? Katrina Firlik, MD examines the impact that caring for others can have on caring for yourself…
by Jeff Elton
Jeff Elton explains how the need for more targeted, personalized therapies, are requiring changes throughout the drug development process, and how best your company can adapt.
by Ifti Ahmed
“I like your product, but it’s too expensive!” How many times has a sales person heard these words and felt trapped? The price or financial component is very important and can mean the difference between a sale or an almost sale – depending on how you approach it of course.
This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.
As payers and providers consolidate and use their market share to enhance negotiations with manufacturers, what can pharma do to protect their business and capture value for their products? This month, I explore the serious implications associated with this trend of healthcare consolidation.
Social media is ever-changing. In reality it’s the community ideals behind blogs, Facebook, podcasts, text messaging, micro-blogging and more, that are fundamental. The cool tools will evolve, change and disappear, but those ideals will always remain.
In this first installment of the newly relaunched Adherence Arena, Katrina Firlik, MD, examines some of the psychological causes of non-adherence and tries to provide some explanation as to why getting a cavity filled might seem more appealing than taking your meds…
by Ifti Ahmed
This month, Ifti Ahmed examines the role of the salesperson in a sales transaction, and explains why simply setting targets might not be enough to make that sale.
In this month’s column we look at Hepatitis C and examine the differences (and similarities) between the causes of non-adherence in China and the US.
In this installment we look at how the value of health information both to the patient and for medical research has been reflected in the recent Health & Social Care Act and discussed in The Review on Information Governance chaired by Dame Fiona Caldicott published in April 2013.
Rita Numerof examines the link between an increased focus on patient adherence, and improved results with industry payers.